Bolt Biotherapeutics, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Bolt Biotherapeutics, Inc. has filed its 2023 annual report (10-K) detailing its operations and financial status.</b>

AI Summary

Bolt Biotherapeutics, Inc. (BOLT) filed a Annual Report (10-K) with the SEC on March 21, 2024. Bolt Biotherapeutics, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. The company's principal executive offices are located at 900 Chesapeake Drive, Redwood City, CA 94063. Bolt Biotherapeutics, Inc. was formerly known as Bolt Therapeutics, Inc. until May 4, 2015. The company is classified under the SIC code 2834 for Pharmaceutical Preparations.

Why It Matters

For investors and stakeholders tracking Bolt Biotherapeutics, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Bolt Biotherapeutics' business, financial condition, and results of operations for the fiscal year 2023, which is crucial for investors to assess the company's performance and future prospects. The detailed information within the 10-K, including risk factors and financial statements, allows stakeholders to understand the company's strategic direction, potential challenges, and overall health.

Risk Assessment

Risk Level: medium — Bolt Biotherapeutics, Inc. shows moderate risk based on this filing. The company operates in the pharmaceutical preparations industry (SIC 2834), which is subject to significant regulatory oversight, lengthy development cycles, and substantial R&D costs, indicating inherent risks.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand Bolt Biotherapeutics' current financial health and strategic outlook.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-03-21 — Filing Date (Date of submission)
• 001-39988 — SEC File Number (Associated SEC file number)
• 0000950170-24-034692 — Accession Number (Unique identifier for the filing)

Key Players & Entities

• Bolt Biotherapeutics, Inc. (company) — Filer name
• Bolt Therapeutics, Inc. (company) — Former company name
• 2023-12-31 (date) — Fiscal year end
• 2024-03-21 (date) — Filing date
• 900 Chesapeake Drive, Redwood City, CA 94063 (address) — Business address
• 2834 (industry) — Standard Industrial Classification

FAQ

Industry Context

Bolt Biotherapeutics operates within the pharmaceutical preparations industry, a sector characterized by extensive research and development, regulatory hurdles, and long product commercialization timelines.

Regulatory Implications

Companies in the pharmaceutical sector are subject to stringent regulations from bodies like the FDA, governing drug development, manufacturing, and marketing, which can impact timelines and costs.

What Investors Should Do

1. Review the full 10-K filing for detailed financial statements and management's discussion and analysis.
2. Analyze the risk factors section to understand potential challenges and uncertainties facing Bolt Biotherapeutics.
3. Compare the company's performance and disclosures in this 10-K with previous filings and industry peers.

Year-Over-Year Comparison

This filing is the 2023 annual report on Form 10-K, providing updated information since the previous fiscal year's filings.

Key Financial Figures

• $0.00001 — nge on which registered Common Stock, $0.00001 par value BOLT The Nasdaq Global Se

Filing Documents

• bolt-20231231.htm (10-K) — 2713KB
• bolt-ex23_1.htm (EX-23.1) — 2KB
• bolt-ex31_1.htm (EX-31.1) — 13KB
• bolt-ex31_2.htm (EX-31.2) — 12KB
• bolt-ex32_1.htm (EX-32.1) — 6KB
• bolt-ex32_2.htm (EX-32.2) — 7KB
• bolt-ex97_1.htm (EX-97.1) — 51KB
• 0000950170-24-034692.txt (&nbsp;) — 10139KB
• bolt-20231231.xsd (EX-101.SCH) — 1288KB
• bolt-20231231_htm.xml (XML) — 1823KB

Business

Business 3 Item 1A.

Risk Factors

Risk Factors 28 Item 1B. Unresolved Staff Comments 71 Item 1C. Cybersecurity 71 Item 2.

Properties

Properties 73 Item 3.

Legal Proceedings

Legal Proceedings 73 Item 4. Mine Safety Disclosures 73 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 74 Item 6. Reserved 74 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 75 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 87 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 88 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 115 Item 9A.

Controls and Procedures

Controls and Procedures 115 Item 9B. Other Information 116 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 116 PART III Item 10. Directors, Executive Officers and Corporate Governance 117 Item 11.

Executive Compensation

Executive Compensation 117 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 117 Item 13. Certain Relationships and Related Transactions, and Director Independence 117 Item 14. Principal Accounting Fees and Services 117 PART IV Item 15. Exhibits and Financial Statement Schedules 118 Item 16 Form 10-K Summary 120

Signatures

Signatures i Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical facts contained in this Annual Report are forward-looking statements, including statements regarding: our expectations regarding the success of our development and commercialization strategy and our product candidates; our expectations regarding the operation of our product candidates, collaborations and related benefits; our beliefs regarding our industry; our beliefs regarding the success, cost and timing of our product candidate development and collaboration activities and current and future clinical trials and studies; our beliefs regarding the potential markets for our product candidates, collaborations and our and our collaborators' ability to serve those markets; our ability to attract and retain key personnel; any impact of pandemics, or responses to the pandemics, on our business, collaborations, clinical trials or personnel; our ability to obtain funding for our operations, including funding necessary to complete further development and any commercialization of our product candidates; and regulatory developments in the United States (the "U.S.") and foreign countries, with respect to our product candidates. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance and achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "anticipates," "believes," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "should," "will," or the negative of these

View Full Filing

View this 10-K filing on SEC EDGAR